Many patients with pancreatic cancer have only about a 10% chance of survival within 5 years of being diagnosed because they tend to become resistant to chemotherapy, previous studies have shown.
A “time machine” designed by Purdue University engineers to observe pancreatic cancer behavior over time suggests a new approach to drug testing could help scientists catch up. resistance to drugs is better.
The researchers found that testing potential drugs on multiple tumor cell classifications – instead of just one cell classifier – could reveal possible drug resistance due to how Different cancer subtypes interact with each other.
The research was recently published in the Royal Society of Chemistry Lab on chip.
Bumsoo Han, professor of mechanical engineering and program leader at Purdue, said: “The drug discovery and screening process used a class of cancer cells and studied how it interacts with non-cells. There must be cancer nearby, but this can overestimate the effectiveness of the drug. Purdue Cancer Research Center. Han has a polite appointment in biomedical engineering.
“By condensing the time it took to look at how cancer cells interact in pancreatic tumors, we found that not only one subtype of cancer cells was more resistant to drugs than others, but more so,” he said. Drug-sensitive cells may also become resistant through interactions between classes. “
A “time machine” is a type of experimental tool called a microfluidic device. These devices are platforms the size of gum strips, such as a chip or slide, where cancer cells can be grown in channels less than one millimeter in diameter. The cells then grow in a lifelike environment on the foundation, such as in a collagen tube that Han’s lab has created to mimic the pancreatic duct.
Microfluidic devices are starting to become more common in drug development as they allow scientists to test drugs in realistic simulations of a biological system using real tissue samples, but on time scale faster than animal models.
Han’s team found that approximately 25% of the 2019 research publications led by PubMed, a biomedical database indexed, used microfluidic devices as a model for dynamic tumor research. objects or patients.
But most microfluidic devices only show late stage tumor growth. With Han’s device, scientists can load cell lines from an animal or patient model before a genetic mutation occurs, making it possible for them to see all stages of tumor progression.
While findings made using microfluidic devices need to be confirmed in humans prior to being put into clinical practice, they can still shorten drug development by offering strategies to new research method.
The findings from Han’s equipment indicate a need to study the interactions between cancer cells.
“There haven’t been a lot of studies on what kind of interactions occur in tumors, so the mechanisms of resistance are ignored,” Han said.
These findings have informed the development of new medicinal compounds.
Zhong-Yin Zhang, director of the Purdue Institute of Drug Discovery, is using Han’s microfluidic device to test a compound to suppress the carcinogenic process that Zhang’s lab previously determined to be. role in cancer development.
The device allowed Zhang’s team to evaluate this compound not only specifically for pancreatic cancer, but also across many subtypes of cancer cells.
“The cool thing about this device is we don’t have to use a lot of compounds to see how well it works,” Zhang said. and Department of Chemistry.
Pancreatic cancer ‘Time Machine’ showing conspiracy changes in cell growth and invasion
Hye-ran Moon et al., A model of pancreatic cancer designed with tumor heterogeneity of controlled mutations, Lab on chip (Year 2020). DOI: 10.1039 / D0LC00707B
Provided by Purdue University
Quote: ‘Time Machine’ providing a new method of testing drugs for pancreatic cancer (2020, October 29) retrieved October 30, 2020 from https://phys.org/news/ 2020-10-machine-pancreatic-cancer-drug-approach.html
This material is the subject for the fake rights. Apart from any fair dealings for academic or personal research purposes, no part may be reproduced without written permission. The content provided is for informational purposes only.